Monitor for continued insider selling in the next 30 days. Given the size of the monetization (~0.018% of market cap), this is not yet alarmingly large, but the concentration of activity in the CEO raises caution. Check upcoming Form 4s for any further dispositions or changes in holdings.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 17 $540.02entry
- T+1 · 8mo ago −1.79%α −0.40% · $530.35
- T+5 · 8mo ago −1.52%α +1.11% · $531.82
- T+20 · 7mo ago +6.96%α +2.61% · $577.58
- T+60 · 5mo ago +1.00%α −8.99% · $545.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics CEO Martine Rothblatt conducted a series of derivative exercises and open-market sales over the past week, including over $2.2 million in share sales. Director Malcolm Jan and Director Judy Olian also sold smaller amounts. The majority of the economic activity stems from Rothblatt monetizing previously held options.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 2,100 shares in open-market transactions totaling ~$1.13 million over three days (March 12–16).
- Rothblatt exercised 38,000 derivative securities across four transactions, with 19,000 at $0 cost and 19,000 at $146.03 strike price, unlocking ~$2.77 million in value.
- Total open-market sales by insiders in the cluster: 2,795 shares, ~$1.43 million.
- Directors Malcolm Jan and Judy Olian sold 45 and 200 shares respectively for $24K and $107K, small relative to CEO activity.
- All transactions occurred between March 12–17 at prices between $532–$535/share.
Financial Impact
$1.43 million in open-market sales by insiders, with $2.77 million in option exercises. Total insider monetization: ~$4.2 million.
Risk Factors
- Sustained insider selling could signal lack of confidence in near-term prospects.
- Option exercises followed by sales may indicate profit-taking ahead of potential headwinds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-UTHR-1773781010511 |
Track record
123 reports on UTHR
3 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers